<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric CancerFrancisco Sánchez-Vega, Yelena Y. Janjigian, Jaclyn F. Hechtman et al.|Cancer Discovery|2018Cited by 147
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal CancerRona Yaeger, Sandra Misale, Riccardo Mezzadra et al.|Cancer Discovery|2022Cited by 144
Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal CancerRona Yaeger, Sandra Misale, Riccardo Mezzadra et al.|Unknown|2023Cited by 0
Data from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal CancerRona Yaeger, Sandra Misale, Riccardo Mezzadra et al.|Unknown|2023Cited by 0
Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal CancerRona Yaeger, Sandra Misale, Riccardo Mezzadra et al.|Unknown|2023Cited by 0